GlaxoSmithKline has signed a research and development agreement with Chroma Therapeutics in a deal potentially worth US$1 B. The two companies are to collaborate on utilising Chroma’s esterase-sensitive motif (ESM) technology to develop inhibitors of inflammatory diseases such as rheumatoid arthritis.